Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): Biomarker and subset results of a phase II randomized discontinuation trial.

Schwartz, G. K.; Maki, Robert G.; Ratain, Mark J.; Undevia, Samir D.; Jones, Robin L.; Rudin, Charles M.; Siu, Lillian L.; Brockstein, B.; Khayat, David; Gil, T.; Jonge, Maja J. De; Sawyer, Michael B.; Evans, T. R. J.; Médioni, Jacques; O’Dwyer, P. J.; Hartman, Christine M.; Poulart, Valerie; Walters, Ian

doi:10.1200/jco.2011.29.15_suppl.10000

Cited by 16 publications

(9 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Brivanib is an oral dual inhibitor of VEGF and fibroblast growth factor (FGF) that was evaluated in a phase II-randomized discontinuation trial in advanced soft tissue sarcomas (Schwartz et al , 2011). In that study, patients that had FGF2 expression by immunohistochemistry appeared to potentially benefit; there was also a suggestion of increased activity in angiosarcoma.…”

Section: Discussionmentioning

confidence: 99%

High-risk features in radiation-associated breast angiosarcomas

et al. 2013

View full text Add to dashboard Cite

Background:Radiation-associated breast angiosarcoma (RT-AS) is an uncommon malignancy with an incidence of less than 1 % of all soft tissue sarcomas. The overall prognosis is quite dismal with high rates of recurrences and poor overall survival. There is an obvious paucity of data regarding clinical outcomes of patients with breast RT-AS.Methods:We identified all patients with RT-AS treated at the Memorial Sloan-Kettering Cancer Center between 1982–2011 and collected their correlative clinical information.Results:We identified 79 women with RT-AS with a median age of 68 (range 36–87). The median interval between radiation and development of RT-AS was 7 years (range 3–19). The median time to local and distant recurrence was 1.29 years (95 % CI 0.72–NA) and 2.48 years (95 % CI 1.29–NA), respectively. The median disease-specific survival was 2.97 years (95 % CI 2.21–NA). Independent predictors of worse disease-specific survival included age ⩾68 years (HR 3.11, 95 % CI 1.20–8.08, P=0.020) and deep tumors (HR 3.23, 95 % CI 1.02–10.21, P=0.046.)Conclusion:RT-AS has high local/distant recurrence rates, limited duration on standard chemotherapy and poor disease-specific survival.

show abstract

Section: Discussionmentioning

confidence: 99%

High-risk features in radiation-associated breast angiosarcomas

et al. 2013

View full text Add to dashboard Cite

show abstract

“…Of the 251 patients with STS enrolled, there were seven partial responses, with an overall response rate of 2.8% and a disease control (overall response rate + stable disease) rate of 30%. Median progression-free survival was 2.8 months from the initial 12-week lead-in period in a subgroup of high expressers of fibroblast growth factor receiving brivanib compared with 1.4 months for placebo controls ( P = 0.08) 18. These laboratory and clinical data suggest that antiangiogenic agents may have a role in the treatment of STS.…”

Section: Antiangiogenic Agents In Soft Tissue Sarcomamentioning

confidence: 82%

Targeted treatment for advanced soft tissue sarcoma: profile of pazopanib

Rajendra

Jones

Pollack

2013

OTT

View full text Add to dashboard Cite

Soft tissue sarcomas comprise approximately 1% of all adult solid malignancies. While chemotherapy is the mainstay of treatment for patients with metastatic or inoperable disease, overall survival for these patients is approximately 12 months, highlighting the need for novel agents. Both laboratory and clinical data have suggested that antiangiogenic agents may have a role in the treatment of soft tissue sarcomas. Pazopanib is a multitargeted receptor tyrosine kinase inhibitor with antiangiogenic activity. The randomized, double-blind, placebo-controlled, Phase III PALETTE (pazopanib for metastatic soft-tissue sarcoma) study demonstrated improved progression-free survival in patients receiving pazopanib compared with placebo. In this review, we discuss the rationale and clinical evidence for the use of pazopanib in the treatment of metastatic and inoperable soft tissue sarcomas.

show abstract

“…Two hundred fifty-one patients with sarcomas of all types (leiomyosarcoma, liposarcoma, angiosarcoma and other were included) [54] Within the first 12 weeks, 168 patients came off study. Median PFS was 2.6 months for patients in the brivanib arm versus 1.4 months in the placebo arm.…”

Section: Targetted Therapy Beyond Pazopanibmentioning

confidence: 99%